Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have earned an average rating of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $16.75.

A number of research firms have weighed in on FOLD. Wells Fargo & Company dropped their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. JPMorgan Chase & Co. increased their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Amicus Therapeutics during the fourth quarter valued at approximately $59,000. Neo Ivy Capital Management increased its holdings in shares of Amicus Therapeutics by 501.6% in the 4th quarter. Neo Ivy Capital Management now owns 395,745 shares of the biopharmaceutical company’s stock worth $3,727,000 after purchasing an additional 329,959 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Amicus Therapeutics by 96.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 958,671 shares of the biopharmaceutical company’s stock worth $9,031,000 after purchasing an additional 471,902 shares during the last quarter. Vestal Point Capital LP purchased a new stake in shares of Amicus Therapeutics during the fourth quarter valued at $31,557,000. Finally, Sovereign s Capital Management LLC bought a new stake in Amicus Therapeutics in the 4th quarter worth about $2,806,000.

Amicus Therapeutics Stock Performance

Shares of FOLD stock opened at $8.63 on Thursday. Amicus Therapeutics has a one year low of $8.55 and a one year high of $12.65. The company has a market cap of $2.65 billion, a P/E ratio of -47.94, a P/E/G ratio of 1.51 and a beta of 0.69. The firm has a 50-day moving average of $9.42 and a 200-day moving average of $10.22. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.